SC
VKTX icon

SouthState Corp’s Viking Therapeutics VKTX Stock Holding History

SouthState Corp’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$391 Hold
10
– – ﹤0.01% 1259
2026
Q1 		$326 Hold
10
– – ﹤0.01% 1229
2025
Q4 		$352 Hold
10
– – ﹤0.01% 1269
2025
Q3 		$263 Hold
10
– – ﹤0.01% 1294
2025
Q2 		$265 Sell
10
-60
-86% -$1.58K ﹤0.01% 1521
2025
Q1 		$1.69K Buy
+70
New +$2.21K ﹤0.01% 1223

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

SouthState Corp's VKTX Position: Q2 2026 in Review

SouthState Corp held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 10 shares worth $391. The position accounts for ﹤0.01% of the portfolio, ranked #1259.

SouthState Corp first reported a position in VKTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.69K in Q1 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • SouthState Corp held 10 shares of Viking Therapeutics worth $391 as of Q2 2026.
  • SouthState Corp left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of SouthState Corp's portfolio in Q2 2026, its #1259 holding.
  • SouthState Corp first reported a position in Viking Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • SouthState Corp's Viking Therapeutics position peaked at $1.69K in Q1 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on SouthState Corp's 13F filing for Q2 2026, filed 6 Aug 2026.